Force for Good

Cipla Limited | Annual Report 2022-23

Pioneering | Innovative | Rooted in Care

Business Responsibility & Sustainability Report

SECTION A:

GENERAL DISCLOSURES

  1. Details of the listed entity1
  1. Corporate Identity Number (CIN) of the Listed Entity –L24239MH1935PLC002380
  2. Name of the listed entity –Cipla Limited
  3. Year of incorporation –1935
  4. Registered office address – Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400013
  5. Corporate address – Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400013
  6. E-mail–cosecretary@cipla.com
  7. Telephone – +91 22 2482 6000
  8. Website –www.cipla.com
  9. Financial year for which reporting is being done –1stApril, 2022 to 31stMarch, 2023
  1. Name of the Stock Exchange(s) where shares are listed –
    1. National Stock Exchange of India Limited
    2. BSE Limited
    3. Societe De La Bourse De Luxembourg (Luxembourg Stock Exchange) for GDRs
  3. Paid-upcapital – H 1,61,43,01,186
  4. Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report-
    1. Name – Mr Rajendra Chopra
    2. Designation – Company Secretary
    3. Telephone Number – +91 22 2482 6000
    4. E-mailID –cosecretary@cipla.com
  6. Reporting boundary – Refer page no. 02 of About this Report

II. Products/services2

14. Details of business activities (accounting for 90% of the turnover)

S.

Description of Main Activity

Description of Business Activity

% of Turnover of the entity

No.

1

Trade

Wholesale trading

19.98

2

Manufacturing

Chemical and chemical products, pharmaceuticals,

72.05

medicinal chemical and botanical products

15. Products/Services sold by the entity (accounting for 90% of the entity’s turnover)

S.

Product/Service

NIC Code 2004

% of total turnover

No.

contributed

1

Manufacture of chemical substances used in the manufacture of

24231

2.29

pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium

derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and

esters; glycosides and vegetable alkaloids; chemically pure sugar etc.

2

Wholesale of pharmaceutical and medical goods

51397

31.30

3

Manufacture of allopathic pharmaceutical preparations

24232

66.41

  1. GRI 2-1
  2. GRI 2-6

Corporate Overview & Integrated Report | Statutory Reports | Financial Statements

III.

Operations3

16.

Number of locations where plants and/or operations/offices of the entity are situated

Location

Number of plants

Number of offices

Total

National

38

55

93

International

9

33

42

17.

Markets served by the entity

a. Number of locations

Locations

Number

National (no. of states)

28 states and 8 Union territories

International (no. of countries)

844
  1. What is the contribution of exports as a percentage of the total turnover of the entity?36.67% (standalone)
  2. A brief on types of customers
    Refer page no. 84 of Relationship Capital

IV.

Employees

18.

Details as at the end of Financial Year

a) Employees and workers (including differently abled):

Refer page no. 66 of Human Capital

b) Differently abled employees and workers:

Refer page no. 66 of Human Capital

19.

Participation/Inclusion/Representation of women

Total(A)

No. and percentage of Females

No.(B)

%(B/A)

Board of Directors

125

2

16.67

Key Management Personnel

4

1

25.00

20.

Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

Refer page no. 75 of Human Capital

V. Holding, Subsidiary and Associate Companies (including joint ventures)

21. (a) Names of holding / subsidiary / associate companies / joint ventures

The details of holding / subsidiary / associate / joint venture companies are given in Form AOC-1, on page no. 369 of this report.

  1. GRI 2-1, GRI 2-6
  2. Represents countries/ markets where sales are more than USD 0.5 million
  3. Dr Peter Mugyenyi, resigned from the position of Independent Director of the Company with effect from 13th May, 2023

Force for Good

Cipla Limited | Annual Report 2022-23

Pioneering | Innovative | Rooted in Care

  1. Does the entity indicated in above form, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
    Yes, all the entities, wherever applicable, participate in the relevant Business Responsibility initiatives of the Company, except associate companies and joint venture companies.

VI. CSR Details

22. (i) Whether CSR is applicable as per Section 135 of Companies Act, 2013: Yes

  1. Turnover – H 15,961.95 crores
  2. Net worth – H 24,632.45 crores

VII. Transparency and Disclosures Compliances

23. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct6

Stakeholder

Grievance Redressal

FY 2022-23

FY 2021-22

Mechanism in Place (Yes/No)

group from

No of

No of complaints

whom

Policy coverage

Number of

Number of

(If Yes, then provide web-link

complaints

pending resolution

complaints

complaints pending

complaint is

Remarks

Remarks

received

for grievance redress policy)

filed during

at close of the

filed during

resolution at close of

the year

year

the year

the year7

https://www.cipla.com/sites/

Communities

default/files/1530274684_

Code of Conduct

–

–

–

–

–

–

Cipla—Code-of-Conduct-FC.

PDF.pdf

Investors

(other than

Not applicable

shareholders)

https://www.cipla.com/

Investor

Shareholders

sites/default/files/Investor-

Servicing and

38

2

–

23

–

–

Servicing-and-Grievance-

Grievance

Redrrssal-Policy.pdf

Redressal Policy

Available on the intranet

Employee

–

–

–

–

–

–

Grievance Policy

https://www.cipla.com/sites/

default/files/1530274684_

Code of Conduct

53

4

–

99

7

–

Cipla—Code-of-Conduct-FC.

PDF.pdf

Employees and

https://www.cipla.com/

Human Rights

workers

sites/default/files/2023-07/

–

–

–

1

–

–

Policy

Human-Rights-Policy.pdf

https://www.cipla.com/sites/

Policy on

default/files/1558508425_

Prevention

POSH-%20Cipla.pdf

of Sexual

7

–

–

9

1

–

Harassment at

the workplace

https://www.cipla.com/

Reporting

contact-us

on adverse /

4,691

992

–

3,415

45

–

technical events

Customers

https://www.cipla.com/sites/

default/files/1530274684_

Code of Conduct

–

–

–

2

–

–

Cipla—Code-of-Conduct-FC.

PDF.pdf
  1. GRI 2-24, GRI 2-25
  2. Code of conduct complaints pending as on 9th May, 2022

Corporate Overview & Integrated Report | Statutory Reports | Financial Statements

Stakeholder

Grievance Redressal

FY 2022-23

FY 2021-22

Mechanism in Place (Yes/No)

group from

No of

No of complaints

whom

Policy coverage

Number of

Number of

(If Yes, then provide web-link

complaints

pending resolution

complaints

complaints pending

complaint is

Remarks

Remarks

received

for grievance redress policy)

filed during

at close of the

filed during

resolution at close of

the year

year

the year

the year7

https://www.cipla.com/sites/

default/files/1530274684_

Code of Conduct

3

–

–

2

–

–

Value Chain

Cipla—Code-of-Conduct-FC.

PDF.pdf

Partners

https://www.cipla.com/

Reporting

contact-us

on adverse /

351

63

–

354

2

–

technical events

https://www.cipla.com/sites/

default/files/1530274684_

Code of Conduct

1

–

–

–

–

–

Cipla—Code-of-Conduct-FC.

HCPs

PDF.pdf

https://www.cipla.com/

Reporting

contact-us

on adverse /

284

47

–

100

4

–

technical events

https://www.cipla.com/

Reporting

contact-us

on adverse /

58

18

–

48

2

–

Government

technical events

https://www.cipla.com/sites/

and Regulators

default/files/1530274684_

Code of Conduct

–

–

–

–

–

–

Cipla—Code-of-Conduct-FC.

PDF.pdf

https://www.cipla.com/sites/

Others

default/files/1530274684_

Code of Conduct

22

6

–

22

2

–

Cipla—Code-of-Conduct-FC.

PDF.pdf

24. Overview of the entity’s material responsible business conduct issues

Please indicate the material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format

Refer page no. 44 of Materiality Assessment

7 Code of conduct complaints pending as on 9th May, 2022

SECTION B:

MANAGEMENT AND PROCESS DISCLOSURES

Sr.

Disclosure Questions

P1

P2

P3

P4

P5

P6

P7

P8

P9

No

Policy and management process8

1

a. Whether your entity’s policy/policies cover

Yes

each principle and its core elements of the

NGRBCs:

b. Has the policy been approved by the

Yes9

Board?

c. Web Link of the Policies, if available

Policies are available on (1) website of the Company – www.cipla.com and (2) Intranet portal of the Company – accessible to the employees of the Company

2

Whether the entity has translated the policy

Yes

into procedures. (Yes / No)

3

Do the enlisted policies extend to your

Yes, Code of Conduct and other applicable policies extends to our value chain partners

value chain partners? (Yes/No)

4

Name of the national and international

GRI Standards

cGMP

Occupational

GRI Standards 2021

Universal

All our manufacturing sites

NA

CSR rules

We follow

codes/certifications/labels/ standards (e.g.

2021,

standards,

Health and Safety

Declaration of

across India are certified

prescribed

National Institute

Forest Stewardship Council, Fairtrade,

OECD Principles

GRI

management system

Human Rights,

for the Environment

by the

of Standards

Rainforest Alliance, Trustea) standards (e.g.

of Corporate

Standards

(ISO 45001:2018) at all

United Nations

Management System ISO

Companies

and Technology,

SA 8000, OHSAS, ISO, BIS) adopted by your

Governance

2021

manufacturing sites

Guiding Principles

14001:2015,

Act, 2013

International

entity and mapped to each principle.

in India

on Business and

Pledged support to ‘Terra

Organisation for

Human Rights, GRI

Carta’,

Standardisation

Standards 2021

GRI Standards 2021, India

(ISO 270001),

Business & Biodiversity

Indian MDR

Initiative (IBBI)

2017 and ISO

13485:2016

standards

(medical devices

manufacturing

units)

5

Specific commitments, goals and targets

The specific commitments, goals and targets are provided in the respective capitals of the Integrated Annual Report, wherever applicable

set by the entity with defined timelines, if any.

6

Performance of the entity against the

specific commitments, goals and targets

The performance against specific commitments, goals and targets are provided in the respective capitals of the Integrated Annual Report, wherever applicable

along-with reasons in case the same are

not met.

  1. GRI 2-24
  2. Policies are approved by the Board, respective board committees, respective department heads, wherever applicable

Pioneering | Innovative

Force for Good

| Rooted in Care

Cipla Limited | Annual Report 2022-23

Attachments


  • Original Link

  • Original Document

  • Permalink

Disclaimer

Cipla Ltd. published this content on 18 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2023 16:40:05 UTC.